Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F1GBM
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,851
Award facts
- Contract value 100% obligated
- $34,851.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 19, 2025, for the supply of DUPIXENT (dupilumab) 300 mg/2 mL pens, with a contract ceiling value of $34,851.13. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award through open competition. The order is set for ultimate completion by December 22, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is well-positioned to fulfill this order as a prime contractor on the DLA Troop Support Medical IDC. The company has an extensive portfolio of federal pharmaceutical contract awards with the Defense Logistics Agency, supplying a comprehensive range of brand-name and generic medications, specialty pharmaceuticals, vaccines, and medical devices across multiple therapeutic domains to support military and veteran healthcare systems. The delivery of DUPIXENT, a biologic medication used for conditions such as moderate-to-severe atopic dermatitis and eosinophilic asthma, aligns with the company's demonstrated capability to provide specialized and high-value pharmaceutical products to federal health programs.
Quick answers
Who was awarded contract SPE2DR26F1GBM?
SPE2DR26F1GBM was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 19, 2025.
How much is contract SPE2DR26F1GBM worth?
The government has obligated $34,851 on SPE2DR26F1GBM.
Is contract SPE2DR26F1GBM an order under another contract?
Yes. SPE2DR26F1GBM is a delivery order under SPE2DR25D2106, an indefinite delivery contract.
Was contract SPE2DR26F1GBM competed?
The extent of competition for SPE2DR26F1GBM was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award